Thermo Fisher Scientific recently announced a strategic data collaboration with Datavant, enhancing the ability of pharmaceutical and biotech companies to connect real-world data with clinical research, thereby accelerating evidence generation. This partnership will leverage Thermo Fisher’s PPD clinical research business alongside Datavant’s data collaboration platform, enabling secure analysis of real-world data (RWD) across various applications, including randomized clinical trials and clinical registries.
Datavant’s technology, which ensures privacy-preserving tokenization and linkage of patient-level data, connects over 350 RWD partners and 80,000 U.S. healthcare facilities. By integrating this technology within Thermo Fisher’s infrastructure, the collaboration aims to provide biopharmaceutical customers with enhanced access to linked patient data and advanced analytics, ultimately facilitating improved study designs and faster recruitment processes.
This partnership aligns with Thermo Fisher’s broader strategy of investing in digital innovation, including collaborations with companies like OpenAI, to enhance value for life sciences customers. As Karen Kaucic, M.D., Chief Medical Officer at Thermo Fisher, noted, data interoperability is essential for the next generation of evidence generation, allowing for a more seamless research experience. The collaboration not only strengthens Thermo Fisher’s leadership in real-world evidence and observational study services but also signifies a commitment to transforming data application in clinical research.
According to Krishna Cheriath, Vice President at Thermo Fisher, integrating Datavant’s capabilities with their own will accelerate insights and improve patient outcomes. This collaboration marks a significant milestone in Thermo Fisher’s ongoing digital transformation efforts, reinforcing its position as a leader in the life sciences sector.
Get started today with Solo access →
